Exscientia Outline Robot and AI Use in Drug Discovery Workflow
Morgan Stanley Maintains Exscientia(EXAI.US) With Hold Rating, Maintains Target Price $5.7
Exscientia Plc (EXAI) Receives a Hold From Morgan Stanley
AI Revolution in Healthcare Gains Momentum as FDA Prepares for Tech Boom
Morgan Stanley Maintains Exscientia(EXAI.US) With Hold Rating, Maintains Target Price $5.7
Morgan Stanley analyst Vikram Purohit maintains $Exscientia(EXAI.US)$ with a hold rating, and maintains the target price at $5.7.According to TipRanks data, the analyst has a success rate of 34.5%
Morgan Stanley Maintains Exscientia(EXAI.US) With Hold Rating, Cuts Target Price to $5.7
Morgan Stanley analyst Vikram Purohit maintains $Exscientia(EXAI.US)$ with a hold rating, and adjusts the target price from $7 to $5.7.According to TipRanks data, the analyst has a success rate of 39.